Brief: Supernus Pharmaceuticals Q2 Product Sales USD 162.5 Million
06/08/2024 21:06
Aug 06 (Reuters) - Supernus Pharmaceuticals Q2 adjusted revenue USD 121.7 million vs. IBES estimate USD 148.9 million. * Q2 operating earnings USD 22.569 million
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing